Zealand Pharma A/S (OTCMKTS:ZLDPF) Announces Quarterly Earnings Results

Zealand Pharma A/S (OTCMKTS:ZLDPF) announced its quarterly earnings data on Thursday. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.96), Zacks reports. Zealand Pharma A/S had a net margin of 68.82% and a return on equity of 41.50%. The firm had revenue of $5.33 million for the quarter, compared to the consensus estimate of $3.77 million.

Zealand Pharma A/S Trading Down 1.4%

Shares of ZLDPF traded down $0.76 during mid-day trading on Friday, reaching $53.52. The company’s stock had a trading volume of 671 shares, compared to its average volume of 2,067. The stock has a market cap of $3.83 billion, a PE ratio of 3.97 and a beta of 0.87. The company has a current ratio of 23.57, a quick ratio of 23.57 and a debt-to-equity ratio of 0.02. Zealand Pharma A/S has a 52 week low of $35.93 and a 52 week high of $83.12. The company’s fifty day moving average price is $46.61 and its two-hundred day moving average price is $62.88.

Analysts Set New Price Targets

Several equities analysts have weighed in on ZLDPF shares. Cantor Fitzgerald reissued a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. BNP Paribas Exane lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Finally, William Blair restated a “market perform” rating on shares of Zealand Pharma A/S in a research report on Friday, March 6th. Three analysts have rated the stock with a Strong Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy”.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.